Presentation is loading. Please wait.

Presentation is loading. Please wait.

By Lucy Abdel Mabood suliman Lecturer of Chest Diseases Faculty of Medicine, Mansoura University.

Similar presentations

Presentation on theme: "By Lucy Abdel Mabood suliman Lecturer of Chest Diseases Faculty of Medicine, Mansoura University."— Presentation transcript:

1 By Lucy Abdel Mabood suliman Lecturer of Chest Diseases Faculty of Medicine, Mansoura University

2  Obstructive Sleepapnea (OSA) is avery common disorder affecting 2%-4% of the adult population.  CPAP is a standard, safe, and efficacious treatment for the obstructive sleep apnea syndrome


4  CPAP  APAP  fixed BIPAP  Auto BIPAP  AVAPS  IVAPS  ASV


6  The functioning of APAP devices can be broken down into three components: sensing of events of SRBD (sensors)  automated computing and analysis of the sensed signals (analysis)  set of algorithms that will determine the action taken by the APAP device in response to the conditions exposed (effectors).

7  In the older generation of APAP devices, the sensors were simplistic and measured only the pressure inflections (vibrations) of a certain frequency and amplitude that were caused by snoring.  The next generation of APAP devices became more sophisticated and were able to sense flow-based changes such as apnea, hypopnea, or inspiratory flow limitation based upon the inspiratory flow contour.

8 1-Auto-titration PAP to determine an effective fixed level of CPAP) 2-Auto-adjusting CPAP for chronic treatment with the advantage of delivering the lowest effective pressure in any circumstance.

9  The devices typically monitor one or more of the following: airflow (or motor speed), airflow profile (flattening), snoring (airway vibration), or airway impedance (forced oscillation technique).  The algorithms used to adjust pressure are proprietary Depending on the type of respiratory event that is detected the delivered pressure is increased by a certain amount.






15  Most APAP devices start with a baseline pressure (usually around 3-4 cm H2O) and then titrate upward as needed.  An absence of monitored events then prompts a gradual decrease in pressure. This allows the minimum effective pressure to be delivered  The APAP devices usually allow the clinician to set maximum and minimum pressure limits.

16 APAP devices allow transfer of pressure over time information to a computer for:-  percentage of time at each pressure (Pmean, P95, and Pmaximum)  detailed information such as leak and persistent apnea/hypopnea counts  The ability to store more than one night of data is useful, as more than one night may be needed to effectively select an appropriate fixed pressure

17  This mode allows a reduction in pressure during early expiration with a return to the current set pressure at end expiration.  This feature could improve patient tolerance to pressure.





22 mask/mouth leak  Tend to raise the baseline flow delivered by blower units and diminish the variations in flow during inspiration and expiration, The resulting airflow signal may be interpreted as an apnea or hypopnea and prompt an increase in pressure that may further increase leak  APAP estimated that leak exceeded 0.4L/s on average for 10% of a supervised night and 15% on an unsupervised night.


24 Central apneas  Central apnea during APAP,Central apneas of the Cheyne-Stokes type are common in patients with severe congestive heart failure (CHF) and also can occur in patients with neurological diseases.


26  Many devices have algorithms that limit pressure increases when leak exceeds certain values or when increases in blower speed no longer result in increases in mask pressure.  some devices have leak alarms that could prompt the patient/staff to readjust the mask.  Mouth leaks could be approached by treating nasal congestion, using heated humidification, chin straps, or using a mask covering the nose and mouth.

27  Some device manufacturers have attempted to identify central apnea by detecting cardiac oscillations in the airflow tracing (open airway apnea).  However, the airway can close in central apnea. Others have designed algorithms that limit the pressure increases for apnea in the absence of associated snoring or airflow limitation.  However, the problem persists in some patients and many of the reviewed clinical trials excluded patients with congestive heart failure.

28  When an apnea has been detected, small oscillations in pressure (1 cm H2O peak-to- peak at 4 Hz) are added to the current device pressure. The CSA algorithm uses the resulting flow and pressure (determined at the mask) to measure the airway patency.

29  This could be performed as an attended study (which allows technologist intervention)  or as an unattended study either in the sleep laboratory or at home  Interventions for mask leaks and the treatment of persistent hypoxemia despite apatent airway with supplemental oxygen would be possible.  However, performing unattended CPAP titration in the sleep laboratory or home is potentially the most useful application of APAP devices.

30  The second potential use for APAP devices is for chronic treatment of OSA.  The difference in pressures needed in REM and NREM (body position, sleep stages)also determines the potential for differences in mean pressure between APAP and CPAP treatment



33  APAP is not recommended to diagnose OSA. (Standard)  Patients with congestive heart failure, significant lung disease such as chronic obstructive pulmonary disease, patients expected to have nocturnal arterial oxyhemoglobin desaturation due to conditions other than OSA (e.g., obesity hypoventilation syndrome), patients who do not snore (either naturally or as a result of palate surgery), and patients who have central sleep apnea syndromes are not currently candidates for APAP titration or treatment. (Standard)

34  APAP devices are not currently recommended for split-night titration. (Standard)  Certain APAP devices may be used during attended titration with polysomnography to identify a single pressure for use with standard CPAP for treatment of moderate to severe OSA. (Guideline)

35  Certain APAP devices may be initiated and used in autotitration and unattended treatment of patients with moderate to severe OSA without significant comorbidities (CHF, COPD, central sleep apnea syndromes, or hypoventilation syndromes). (Option)

36  A reevaluation and, if necessary, a standard attended CPAP titration should be performed if symptoms do not resolve or if the APAP treatment otherwise appears to lack efficacy.(Standard)


Download ppt "By Lucy Abdel Mabood suliman Lecturer of Chest Diseases Faculty of Medicine, Mansoura University."

Similar presentations

Ads by Google